Herlinde Dumez

7.4k total citations
145 papers, 4.8k citations indexed

About

Herlinde Dumez is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Herlinde Dumez has authored 145 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Oncology, 75 papers in Pulmonary and Respiratory Medicine and 32 papers in Molecular Biology. Recurrent topics in Herlinde Dumez's work include Cancer Treatment and Pharmacology (29 papers), Sarcoma Diagnosis and Treatment (20 papers) and Renal cell carcinoma treatment (15 papers). Herlinde Dumez is often cited by papers focused on Cancer Treatment and Pharmacology (29 papers), Sarcoma Diagnosis and Treatment (20 papers) and Renal cell carcinoma treatment (15 papers). Herlinde Dumez collaborates with scholars based in Belgium, Netherlands and United States. Herlinde Dumez's co-authors include Patrick Schöffski, Raf Sciot, A. van Oosterom, Jaap Verweij, Saša Dimitrijević, Pascal Wolter, Maria Dêbiec‐Rychter, A.T. van Oosterom, Allan T. van Oosterom and M. van Glabbeke and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Cancer Research.

In The Last Decade

Herlinde Dumez

141 papers receiving 4.7k citations

Peers

Countries citing papers authored by Herlinde Dumez

Since Specialization

Citations

This map shows the geographic impact of Herlinde Dumez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Herlinde Dumez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Herlinde Dumez more than expected).

Fields of papers citing papers by Herlinde Dumez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Herlinde Dumez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Herlinde Dumez. The network helps show where Herlinde Dumez may publish in the future.

Co-authorship network of co-authors of Herlinde Dumez

This figure shows the co-authorship network connecting the top 25 collaborators of Herlinde Dumez. A scholar is included among the top collaborators of Herlinde Dumez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Herlinde Dumez. Herlinde Dumez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours 2022 ·European Journal of Cancer ·Patrick Schöffski, Ahmad Awada, (unknown), (unknown), Mike F. Burbridge, (unknown), Riccardo Colombo, (unknown), (unknown), Maja J.A. de Jonge, Philippe Aftimos, Herlinde Dumez, Stefan Sleijfer	21
2	Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses 2022 ·The Oncologist ·Niven Mehra, Karim Fizazi, Johann S. de Bono, Philippe Barthélémy, Tanya B. Dorff, (unknown), Jean‐Pascal Machiels, Davide Bimbatti, Deepak Kilari, Herlinde Dumez, Consuelo Buttigliero, Inge M. van Oort, Elena Castro, Hsiang-Chun Chen, Nicola Di Santo, (unknown), Cynthia G. Healy, Giorgio V. Scagliotti	11
3	SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival? 2022 ·BMC Cancer ·(unknown), Charlien Berghen, Filip Ameye, (unknown), (unknown), (unknown), Herlinde Dumez, (unknown), (unknown), Annouschka Laenen, (unknown), Kenneth Poels, Carl Salembier, (unknown), (unknown), (unknown), Steven Joniau, (unknown)	4
4	580P TALAPRO-1: Talazoparib (TALA) monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm) - Exploration of non-DDR mutational landscape and potential associations with antitumor activity 2021 ·Annals of Oncology ·(unknown), Johann S. de Bono, Alexander Laird, Philippe Barthélémy, R. Delva, Tanya B. Dorff, Marco Maruzzo, A. Stirling, J-P. Machiels, Herlinde Dumez, Vincent Renard, Julia F. Hopkins, Lee A. Albacker, Hsiang‐Cheng Chen, Cynthia G. Healy, Jijumon Chelliserry, Inge M. van Oort, Giorgio V. Scagliotti, Karim Fizazi	1
5	Establishment, characterization and imaging of a first platinum-resistant penile cancer patient derived xenograft in nude mice: An eUROGEN project 2020 ·European Urology Open Science ·Maarten Albersen, (unknown), (unknown), Uroš Milenković, Herlinde Dumez, Gert De Meerleer, Steven Joniau, Wouter Everaerts, Igor Tsaur, (unknown), Uwe Himmelreich, Christopher Cawthorne, Christophe M. Deroose, Lien Spans, Isabelle Vanden Bempt, Eleonora Leucci, Anne‐Sophie Van Rompuy, Lara Rizzotto	1
6	Clinical Presentation, Natural History, and Therapeutic Approach in Patients with Solitary Fibrous Tumor: A Retrospective Analysis 2020 ·Sarcoma ·Patrick Schöffski, (unknown), Daphne Hompes, M. Stas, Friedl Sinnaeve, Paul De Leyn, Willy Coosemans, Dirk Van Raemdonck, Esther Hauben, Raf Sciot, Paul M. Clément, Oliver Bechter, Benoit Beuselinck, Feng Jung Sherida H. Woei-A-Jin, Herlinde Dumez, Philippe Nafteux, (unknown)	23
7	A phase I dose-escalation and pharmacokinetic study of a micellar nanoparticle with entrapped docetaxel (CPC634) in patients with advanced solid tumours 2020 ·Journal of Controlled Release ·Florence Atrafi, Herlinde Dumez, Ron H.J. Mathijssen, C. Willemien Menke‐van der Houven van Oordt, Cristianne J.F. Rijcken, Rob Hanssen, Ferry A.L.M. Eskens, Patrick Schöffski	39
8	Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib 2018 ·Clinical Genitourinary Cancer ·Maxime Vanmechelen, Diether Lambrechts, Thomas Van Brussel, Annelies Verbiest, Gabrielle Couchy, Patrick Schöffski, Herlinde Dumez, Philip R. Debruyne, Evelyne Lerut, Jean‐Pascal Machiels, Vincent R. Richard, Maarten Albersen, Vincent Verschaeve, Stéphane Oudard, Arnaud Méjean, Pascal Wolter, Jessica Zucman‐Rossi, Benoit Beuselinck	4
9	Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab 2017 ·Acta Clinica Belgica ·(unknown), Thomas Van Cann, Patrick Schöffski, Paul Clement, Oliver Bechter, Isabel Spriet, Ruxandra Coropciuc, Constantinus Politis, (unknown), Joseph Schoenaers, Herlinde Dumez, Patrick Berteloot, Patrick Neven, Kristiaan Nackaerts, Feng Jung Sherida H. Woei-A-Jin, Kevin Punie, Hans Wildiers, Benoit Beuselinck	40
10	First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumours 2017 ·European Journal of Cancer ·Patrick Schöffski, Jean‐Pierre Delord, Étienne Brain, Jacques Robert, Herlinde Dumez, (unknown), André Trouet	14
11	Single-Centre Experience of Systemic Treatment with Vincristine, Ifosfamide, and Doxorubicin Alternating with Etoposide, Ifosfamide, and Cisplatin in Adult Patients with Ewing Sarcoma 2017 ·Sarcoma ·(unknown), Paul M. Clément, Oliver Bechter, Herlinde Dumez, Annelies Verbiest, Raf Sciot, Daphne Hompes, Friedl Sinnaeve, Erik Van Limbergen, Patrick Schöffski	1
12	18F-MK-9470 PET imaging of the type 1 cannabinoid receptor in prostate carcinoma: a pilot study 2013 ·EJNMMI Research ·(unknown), Michel Koole, Cindy Casteels, Laura Van den Bergh, Guy Bormans, Filip Claus, Liesbeth De Wever, Evelyne Lerut, Hendrik Van Poppel, Steven Joniau, Herlinde Dumez, Karin Haustermans, Luc Mortelmans, Karolien Goffin, Koen Van Laere, Christophe M. Deroose, Felix M. Mottaghy	1
13	Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788 2012 ·Clinical Cancer Research ·José Baselga, Alain C. Mita, Patrick Schöffski, Herlinde Dumez, Federico Rojo, Josep Tabernero, Clifford DiLea, William Mietlowski, (unknown), (unknown), Margaret Dugan, Kathryn Parker, Eric Walk, A. van Oosterom, Erika Martinelli, Chris H. Takimoto	14
14	Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies 2011 ·Cancer Chemotherapy and Pharmacology ·Patrick Schöffski, Herlinde Dumez, Rita Ruijter, (unknown), Arturo Soto-Matos, Vicente Alfaro, Giuseppe Giaccone	26
15	Thyroid dysfunction in patients treated with Sunitinib (SU11248) - A single center retrospective and prospective evaluation 2006 ·Annals of Oncology ·Pascal Wolter, Hans Wildiers, Hans Prenen, (unknown), Herlinde Dumez, Patrick Schöffski	0
16	Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review 2006 ·Annals of Oncology ·Patrick Schöffski, Herlinde Dumez, Paul M. Clément, Ann Hoeben, Hans Prenen, Pascal Wolter, Steven Joniau, Tania Roskams, Hendrik Van Poppel	71
17	Combined anti-EGFR blockade: A phase I pharmacokinetic and molecular pharmacodynamic study of Cetuximab (Erbitux (R)) and Gefitinib (Iressa (R)) in patients with advanced colorectal, head and neck and non-small cell lung cancer expressing the EGFR 2005 ·Clinical Cancer Research ·Josep Tabernero, Patrick Schöffski, Federico Rojo, Ernst de Bruijn, (unknown), Herlinde Dumez, Teresa Macarulla, Hans Prenen, E. Casado, Gunther Guetens, (unknown), (unknown), (unknown), (unknown), Santiago Ramón y Cajal, (unknown), (unknown), A. Van Oosterom, José Baselga	4
18	Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants 2005 ·Gastroenterology ·Maria Dêbiec‐Rychter, Jan Cools, Herlinde Dumez, Raf Sciot, Michel Stul, Nicole Mentens, Hilde Vranckx, Bartosz Wasąg, Hans Prenen, Johannes Roesel, Anne Hagemeijer, A. van Oosterom, Peter Marynen	396
19	Human Red Blood Cells: Rheological Aspects, Uptake, and Release of Cytotoxic Drugs 2004 ·Critical Reviews in Clinical Laboratory Sciences ·Herlinde Dumez, Walter H. Reinhart, Gunther Guetens, E. A. de Bruijn	30
20	Impact of dose-intensity of adjuvant CMF on disease-free (DFS) and overall survival (OS) in breast cancer (BC): a retrospective analysis 2002 ·Annals of Oncology ·Robert Paridaens, J. Wildiers, Herlinde Dumez, (unknown), Caroline Weltens, Walter Van den Bogaert, Erik Van Limbergen, An Aerts, (unknown), A. van Oosterom	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact